NCT01462786View on ClinicalTrials.gov

To Evaluate the Safety, Tolerability and to Compare the Pharmacokinetic Profile of ATX-101

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

November 30, 2011

Study Completion Date

December 31, 2011

Conditions
Healthy
Interventions
DRUG

ATX-101

2 mg/cm2 ATX-101

Trial Locations (1)

58104

Cetero Research, Fargo

Sponsors
All Listed Sponsors
lead

Kythera Biopharmaceuticals

INDUSTRY

NCT01462786 - To Evaluate the Safety, Tolerability and to Compare the Pharmacokinetic Profile of ATX-101 | Biotech Hunter | Biotech Hunter